Open Label Safety Study Shows Improved Sleep for Children With ADHD After One Month of AZSTARYS® (serdexmethylphenidate and dexmethylphenidate)

/PRNewswire/ -- Corium, Inc., a fully integrated biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS)...

Related Keywords

Boston ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Gurnet Point ,American ,Serdexmethylphenidate Dexmethylphenidate ,Andrewj Cutler ,Gregw Mattingly ,Meg Corliss ,Jose Estrada ,Greg Mattingly ,Adolesc Psychopharmacol ,Annc Childress ,Laboratory Classroom Study Of Serdexmethylphenidate ,Psych Congress ,Corium Inc ,American Professional Society ,Prnewswire Corium Inc ,Washington University School Of Medicine ,Dexmethylphenidate Effects ,Sleep Habits Questionnaire ,Washington University School ,Chief Medical Officer ,Open Label Safety ,Children With ,Important Safety Information ,Attention Deficit Hyperactivity Disorder ,Pre Existing Psychosis ,Manic Episode ,Bipolar Disorder ,New Psychotic ,Manic Symptoms ,Prescribing Information ,Medication Guide ,Gurnet Point Capital ,Point Capital ,Controlled Laboratory Classroom Study ,Methylphenidate Capsules ,Corium ,Nc ,